TP53 Arg72Pro and XPD Lys751Gln Gene Polymorphisms and Risk of Lung Cancer in Bangladeshi Patients

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2020 Jul 27

PMID 32711437

Citations 3

Authors

Tahsin Nairuz

Mostafijur Rahman

Most Umme Bushra

Yearul Kabir

Affiliations

Soon will be listed here.

Abstract

Background: Tumor suppressor gene (TP53) is considered as the most frequently mutated gene in almost all forms of human cancer. Moreover, genetic variations in the XPD gene affect the DNA repair capacity increasing cancer susceptibility. Polymorphisms within these genes can play a major role in determining individual lung cancer susceptibility. However, several studies have investigated this possibility; but reported conflicting results. Therefore, the objective of this study was to investigate the role of TP53 Arg72Pro and XPD Lys751Gln gene polymorphisms on lung cancer susceptibility in the Bangladeshi population.

Materials And Methods: Study subjects comprised of 180 lung cancer patients and 200 healthy volunteers. Genetic polymorphism of TP53 was determined by multiplex PCR-based method, while XPD genotypes were analyzed using Polymerase Chain Reaction-based Restriction Fragment Length Polymorphism (PCR-RFLP) method. Lung cancer risk was estimated as odds ratio (OR) and 95% confidence interval (CI).

Results: From the results, no significant association between TP53 Arg72Pro polymorphism and lung cancer risk was observed. Whereas, patients with homozygous mutant variants (Gln/Gln) of XPD at codon 751 were found significantly associated with lung cancer risk when compared to the control (OR=3.58; 95% CI=1.58-8.09; p=0.002). Lung cancer risk was found significantly higher with Gln/Gln variants of XPD among smokers (OR=4.03; 95% CI=1.11-14.63; p=0.026). Significant increased risk of lung cancer was found with Arg/Pro genotypes of TP53, Lys/Gln and Gln/Gln variants of XPD in individuals with family history of cancer (OR=3.44; 95% CI=1.36-8.72; p=0.011; OR=3.17; 95% CI=1.20-8.39; p=0.024; OR=16.35; 95% CI=0.92-289.5; p=0.007, respectively).

Conclusion: The findings indicated that homozygous mutant variants (Gln/Gln) of XPD were associated with increased lung cancer risk, whereas TP53 Arg72Pro polymorphism was not associated with risk of lung cancer among Bangladeshi patients.<br />.

Citing Articles

Novel role of general transcript factor IIH subunit 2 (GTF2H2) in the development and sex disparity of hepatocellular carcinoma.

Li Y, OuYang Q, Chen Z, Zhou D, Li Z, Yang X Oncogene. 2025; .

PMID: 39972070 DOI: 10.1038/s41388-025-03301-7.

Role of GSTM1 and GSTT1 Gene Polymorphisms on Lung Cancer Susceptibility and Effect on Platinum-Based Chemotherapy-Induced Toxicity in Bangladeshi Lung Cancer Patients.

Nairuz T, Kabir Y J Cancer Epidemiol. 2024; 2024:9194714.

PMID: 39619061 PMC: 11606684. DOI: 10.1155/jcep/9194714.

Association of Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men.

Duncan A, Nousome D, Ricks R, Kuo H, Ravindranath L, Dobi A Biomedicines. 2023; 11(5).

PMID: 37239075 PMC: 10216554. DOI: 10.3390/biomedicines11051404.

A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh.

Babu G, Bin Islam S, Khan M Mol Biol Rep. 2022; 49(7):6725-6739.

PMID: 35277785 DOI: 10.1007/s11033-022-07282-8.

References

Wang Y, Chen C, Chen S, Chang Y, Lin P . p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res. 1999; 5(1):129-34. View

Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y . EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. Epidemiology. 2005; 17(1):89-99. DOI: 10.1097/01.ede.0000187627.70026.23. View

Travis W . Pathology of lung cancer. Clin Chest Med. 2011; 32(4):669-92. DOI: 10.1016/j.ccm.2011.08.005. View

Han J, Lee G, Jang D, Lee S, Lee J . Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer. 2008; 113(4):799-807. DOI: 10.1002/cncr.23668. View

Mostaid M, Ahmed M, Islam M, Sayeed M, Hasnat A . Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population. Tumour Biol. 2014; 35(10):10309-17. DOI: 10.1007/s13277-014-2285-2. View

Matakidou A, Eisen T, Houlston R . TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis. 2003; 18(4):377-85. DOI: 10.1093/mutage/geg008. View

Vousden K . p53: death star. Cell. 2000; 103(5):691-4. DOI: 10.1016/s0092-8674(00)00171-9. View

Weston A, Perrin L, Forrester K, Hoover R, Trump B, Harris C . Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev. 1992; 1(6):481-3. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G . Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer. 2006; 52(1):9-14. DOI: 10.1016/j.lungcan.2005.12.007. View

11.

Lind H, Ekstrom P, Ryberg D, Skaug V, Andreassen T, Stangeland L . Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(10):2077-81. DOI: 10.1158/1055-9965.EPI-07-0153. View

12.

Mitra A, Singh N, Garg V, Chaturvedi R, Sharma M, Rath S . Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to Squamous Cell Carcinomas of the Head and Neck (SCCHN) and Breast cancer in the north Indian population. J Exp Clin Cancer Res. 2009; 28:104. PMC: 2724389. DOI: 10.1186/1756-9966-28-104. View

13.

Torok S, Hegedus B, Laszlo V, Hoda M, Ghanim B, Berger W . Lung cancer in never smokers. Future Oncol. 2011; 7(10):1195-211. DOI: 10.2217/fon.11.100. View

14.

Wang S, Lan X, Tan S, Wang S, Li Y . P53 codon 72 Arg/Pro polymorphism and lung cancer risk in Asians: an updated meta-analysis. Tumour Biol. 2013; 34(5):2511-20. PMC: 3785706. DOI: 10.1007/s13277-013-0678-2. View

15.

Nigro J, Baker S, Preisinger A, Jessup J, Hostetter R, Cleary K . Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989; 342(6250):705-8. DOI: 10.1038/342705a0. View

16.

Zhou W, Liu G, Miller D, Thurston S, Xu L, Wain J . Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. Cancer Res. 2002; 62(5):1377-81. View

17.

Jung H, Whang Y, Sung J, Shin H, Park B, Kim J . Association study of TP53 polymorphisms with lung cancer in a Korean population. J Hum Genet. 2008; 53(6):508. DOI: 10.1007/s10038-008-0278-y. View

18.

Mechanic L, Bowman E, Welsh J, Khan M, Hagiwara N, Enewold L . Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev. 2007; 16(2):214-22. DOI: 10.1158/1055-9965.EPI-06-0790. View

19.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

20.

Takahashi T, Nau M, Chiba I, Birrer M, Rosenberg R, Vinocour M . p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989; 246(4929):491-4. DOI: 10.1126/science.2554494. View